Wave Life Sciences retains a Hold rating as WVE-007's Phase 1 data show target engagement and visceral fat reduction but minimal weight loss. WVE-007's efficacy in obesity remains unproven versus ...

The biotech's investigational weight loss drug did very well in a clinical trial. This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the ...

Wave Life Sciences is rated Hold, reflecting high pipeline potential but significant clinical, regulatory, and commercial risks. WVE-006 regaining global rights from GSK raises both opportunity and ...

Wave Life Sciences (WVE) shares rallied 8.8% in the last trading session to close at $8.26. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the low priced stocks to buy with high upside potential. On December 8, Wave Life Sciences announced positive interim results from its Phase 1 INLIGHT ...

Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best stocks under $25 to buy now. On December 16, Oppenheimer boosted its price target for Wave Life Sciences Ltd. (NASDAQ:WVE) to $32 from $24, ...

Wave Life Sciences Ltd (NASDAQ:WVE) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. On February 2, Wave Life Sciences Ltd. (NASDAQ:WVE) said it regained full rights to WVE-006, a ...

Wave Life Sciences Ltd is a pioneering force in genetic medicine, focusing on creating innovative treatments for serious diseases. With its proprietary PRISM platform, the company specializes in ...

Before market open, Wave presented interim data from a phase 1 clinical trial of its WVE-007 weight loss drug. The treatment was found to reduce total body fat in its recipients by 4.5% over the three ...